Media about us

• NovaMedica, Pharmsynthez to create integrated drug production

  19 June 2019 AKM News

  

  Russian drug companies NovaMedica and Pharmsynthez have launched a joint project to make a number of effective drugs available to Russian patients within 1.5-2 years. Integrated local production of these drugs will be set up in Russia, RUSNANO informed.

• Para la transferencia de tecnologías... ¡Estate preparado!

  18 April 2019 GMP News

  

  Si quiere atraer a un socio internacional (proveedor) para localizar en su empresa sus productos, debe seguir con exactitudm las normas internacionales. Conocer y ser capaz de realizar transferencia correctamente. Al parecer, no hay de que discutir. Pero aun, prevalecen los antiguos enfoques en la organization de transferencia de tecnologias farmaceuticas: "Escribannos los componentes, y nosotros lo dominaremos todo aqui por nuestra cuenta".

• Bilfinger soll Pharmaanlage für Novamedica liefern

  11 February 2019 Chemic Technic

  

  Der Mannheimer Industriedienstleister Bilfinger hat vom russischen Pharmaunternehmen Novamedica den Auftrag zur Lieferung einer Arzneimittel-Produktionsanlage erhalten. Das Projekt soll von Bilfinger Industrietechnik Salzburg abgewickelt werden und umfasst die Konstruktion und Errichtung von drei Ansatzsystemen zur Herstellung steriler Arzneiformen. Es ist der erste Auftrag für das Bilfinger-Tochterunternehmen Russland. 

• Import Substitution and Innovations of Kaluga Pharmaceutical Cluster. Results of 2018

  22 January 2019 CIS GMP News, 3 (4) / Winter 2019

  

  For seven years past from its existence Kaluga Pharmaceutical Cluster has been dynamically developing significantly exceeding the growth rates in other economic sectors of the region. And the question is not only about opening of manufacturing facilities but also about further localization and extension of manufacturing capacity of already existing plants of both Russian and foreign manufacturers. 2018 was no exception. In March of 2018, NovaMedica LLC concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga Region. 

• New Chlamydia Test Delivers Results in About 30 Minutes

  11 December 2018 National Institutes of Health

  

  NIBIB-funded researchers recently validated a rapid STD test that delivered accurate results in about 30 minutes for chlamydia, allowing patients to receive treatment immediately, thereby stemming the further spread of disease. Other analyses showed most women preferred the easy self-collection method the test offers.

  
   

• Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium

  07 November 2018 GenomeWeb

  

  Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients. The Canadian centers include Mount Sinai Hospital's Marvelle Koffler Breast Centre, the Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, and BC Cancer.

• PharmNews: NovaMedica Innotech debuts on CPhI

  09 October 2018

  

  The international exhibition CPhI has started in Madrid. And today NovaMedica Innotech is in our focus as the company that has made a bright debut at the exhibition. This Technological Center has launched in April 2017 and Moscow Mayor Sergei Sobyanin attended the opening ceremony.

• How Can the Russian R&D Industry Help the Global One?

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  The current model of the pharmaceutical business in the context of R&D in Russia reflects the world trends. One of the striking examples is R&D Center of NovaMedica Innotech. It belongs to the group of CDMO (contract development and manufacturing organizations), whose task is to provide services following the 'one contact’ principle: pharmaceutical development, technology development, technology transfer, and manufacturing of small batches of products - both for clinical trials and for manufacturing of finished products batches (based on the GMP license).

• The “Pharma-2030” Strategy: Promoting Globalization

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  The pharmaceutical market has been actively discussing Pharma-2030 Strategy, which is currently being developed. The opinions and assessments that we hear are often quite different, if not diametrically opposite. The concept of the program must incorporate the interests of all market participants, including manufacturers, who must understand the general trend, the goals and objectives for further development, and the resources they have available for that work. We asked Alexander Kuzin, General Director of NovaMedica Company, to share his opinion of the program as a representative of the manufacturing sector.

• Kaluga Pharmaceutical Cluster

  03 October 2018 CIS GMP news Magazine, Autumn 2018

  

  Business gave credence to the government course of developing pharmaceutics. Interview with Vice-Governor of Kaluga Region Vladimir Popov: This year, NovaMedica Company got approval for the conclusion of special investment contract. NovaMedica Company will additionally invest more than 3 billion rubles in modernization of its plant and in technology transfer within the frame of this contract.